CTOs on the Move


 
BIOCiS is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.biocis.org
  • 18 1st St
    Cambridge, MA USA 02141
  • Phone: 617.444.8727

Executives

Name Title Contact Details

Similar Companies

Canadian Light Source

Canadian Light Source is a Saskatoon, SK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Seventh Wave

Seventh Wave is a Chesterfield, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Diagnostic Solutions Laboratory

We are pleased to offer clinicians the first of many advances, the GI-MAP™. The GI-MAP™ (GI-Microbial Assay Plus) stool test utilizes cutting edge, FDA-approved technology to provide a true DNA/PCR based stool analysis which provides actionable informa...

BioInnovation Capital

BioInnovation Capital invests in the most promising life science companies in residence at premier co-working laboratory facilities where our partners are on-site every day. As the first investment platform to knit together a national network of co-working laboratories, we have a unique lens and an unparalleled position from which to invest. Our partners are located in: Cambridge, MA (BioLabs and LabCentral); Durham, North Carolina (BioLabs North Carolina); San Francisco, and San Diego, CA (BioLabs San Diego).​ Our perspective is characterized by superb access to key innovators in academia, as well as to the corporate partners who are likely eventual homes for our investments. The geographic nature of innovation hubs and our overlapping network of facilities and resources, supports the formation of stellar companies from the most powerful universities, research institutions, hospitals and corporations in our sector.

DiCE Molecules

At DiCE Molecules, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms.